Allogeneic hematopoietic cell transplantation may alleviate the negative prognostic impact of monosomal and complex karyotypes on patients with acute myeloid leukemia.
Monosomal karyotype (MK) and complex karyotype (CK) are well known to be associated with a very poor clinical outcome in patients with acute myeloid leukemia (AML). However, whether or not the prognostic impact of MK and CK remains relevant for patients who have undergone allogeneic hematopoietic cell transplantation (allo-HCT) is still unclear. We retrospectively analyzed the status of MK and CK, as well as other clinical laboratory features, in 148 allo-HCT AML patients at our institution and correlated with their event-free survival (EFS) and overall survival (OS) after transplantation. MK and CK were identified in 14 (9%) and 19 (13%) cases, respectively. On univariate analysis, only age (≥60 years) and WBC count (≥15 × 10(9)/L) were significant adverse predictors for EFS (P < .001 and P = .017, respectively) and OS (P = .002 and P = .021, respectively). MK, CK, and other relevant parameters analyzed did not affect the clinical outcome. Multivariable analysis confirmed that both older age and high WBC count were independent prognostic factors for a shorter OS (P = .001 and P = .003, respectively) and a shorter EFS (P < .001 and P = .001, respectively). Our results indicate that neither MK nor CK are high-risk factors in AML patients undergoing allo-HCT.
Department of Laboratory Hematology and Pathology, University Health Network, Toronto, Ontario, Canada.
Robert J
RJ
Guo
Department of Biostatistics, University Health Network, Toronto, Ontario, Canada.
Eshetu G
EG
Atenafu
Department of Laboratory Hematology and Pathology, University Health Network, Toronto, Ontario, Canada.
Ken
K
Craddock
Department of Laboratory Hematology and Pathology, University Health Network, Toronto, Ontario, Canada. Electronic address: hong.chang@uhn.on.ca.
Hong
H
Chang
D000367:Age Factors; D000368:Aged; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016130:Immunophenotyping; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009006:Monosomy / Q000276:immunology / Q000473:pathology*; D019653:Myeloablative Agonists / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
D019653:Myeloablative Agonists
Acute myeloid leukemia; Allogeneic stem cell transplantation; Complex karyotype; Cytogenetics; Immunophenotyping; Monosomal karyotype; Prognosis